Ad
related to: b-lymphocyte stimulator
Search results
Results from the WOW.Com Content Network
Belimumab (Benlysta) is a monoclonal antibody developed by Human Genome Sciences and GlaxoSmithKline, with significant discovery input by Cambridge Antibody Technology, which specifically recognizes and inhibits the biological activity of B-Lymphocyte stimulator (BLyS) and is in clinical trials for treatment of Systemic lupus erythematosus and ...
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [8] and Canada, [9] and the European Union [5] to treat systemic lupus erythematosus and lupus nephritis. [10]
Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. [1] It is currently under active investigation in clinical trials. [2]
B cells, unlike the other two classes of lymphocytes, T cells and natural killer cells, express B cell receptors (BCRs) on their cell membrane. [1] BCRs allow the B cell to bind to a foreign antigen, against which it will initiate an antibody response. [1] B cell receptors are extremely specific, with all BCRs on a B cell recognizing the same ...
Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease.The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells - B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin. [1]
Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases. [3] [4] [5] It is primarily expressed by macrophages, monocytes and dendritic cells. [6]
Co-stimulation of the B cell by activated T cell resulting in its complete activation. Proliferation [note 4] of B cells with resultant production of soluble antibodies. Steps in production of antibodies by B cells: 1. Antigen is recognized and engulfed by B cell 2. Antigen is processed 3. Processed antigen is presented on B cell surface 4.
T independent antigens elicit antibody production by B lymphocytes without T lymphocyte involvement. There are two distinct subgroups of TI antigens, different in mechanism of activating B lymphocytes: TI-1 antigen, which has an activity that can directly activate B cells and TI-2 antigen, which has highly repetitive structure and causes simultaneous cross-linking of specific B cell receptors ...
Ad
related to: b-lymphocyte stimulator